Key Highlights
- Valneva shares are up 27.17% in pre-market trading to $7.18, extending Thursday's 1.80% close gain to $5.65.
- The European Medicines Agency validated the Marketing Authorization Application for PF-07307405, the 6-valent Lyme disease Vaccine candidate co-developed with Pfizer, and will now begin its formal review.
- The application is based on Phase 3 VALOR trial results showing more than 70% efficacy in preventing Lyme disease, with no safety concerns identified.
- The milestone comes a day after Valneva reported weak first-half 2026 results, including Revenue down 33% to EUR65.8 million and a wider net loss of EUR63.3 million.
What's Driving the Surge
Valneva SE (NASDAQ:VALN) shares are surging in pre-market trading after the European Medicines Agency (EMA) validated the Marketing Authorization Application (MAA) for PF-07307405, the company's 6-valent outer surface protein A (OspA)-based Lyme disease vaccine candidate developed in Partnership with Pfizer. Validation means the EMA has accepted the application for formal review, marking a significant regulatory milestone for what would be the first Lyme disease vaccine of its kind approved in Europe. Valneva is a France-based specialty vaccine company headquartered in Saint-Herblain, focused on prophylactic vaccines for infectious diseases with unmet medical need.
The application is supported by results from the Phase 3 VALOR trial, which evaluated whether the vaccine candidate prevented Lyme disease in individuals aged five and older. The trial showed efficacy of more than 70%, with the vaccine well tolerated and no safety concerns identified. Lyme disease is described as the most common vector-borne illness in Europe, affecting more than 100,000 people annually, with over 200 million people living in risk areas across the region.
Weighing the Milestone Against Recent Results
The regulatory news arrives just one day after Valneva reported weak first-half 2026 financial results, with revenue down 33% to EUR65.8 million and a wider net loss of EUR63.3 million, alongside a reaffirmed full-year cash position guidance of EUR121.5 million. Investors appear to be looking past the softer core vaccine sales and ongoing restructuring efforts, including a planned site sale in Nantes, to focus instead on the de-risking of the Lyme vaccine program. Analysts remain split on the stock: TD Cowen, recently upgraded to Strong Buy, holds a $12 price target, while Goldman Sachs remains bearish with a Sell rating and a $4.90 target.
Conclusion
Valneva shares are sharply higher in pre-market trading as the EMA's validation of the Lyme disease vaccine application marks a major de-risking event for the company's most closely watched pipeline asset, even as underlying commercial results remain under pressure. With analyst views still divided on valuation, the stock's next moves are likely to hinge on how the EMA review progresses relative to the company's core vaccine business.






Please wait processing your request...